quency of steroid use for ARTIs in Louisiana and nationally and to examine factors associated with this clinical practice.
Methods | Study Settings and Populations.
We conducted a retrospective observational study of adults who had outpatient ambulatory care encounters that included an ARTI diagnosis (otitis, upper respiratory infection, sinusitis, pharyngitis, bronchitis, allergic rhinitis, influenza, and pneumonia) through Ochsner Health System primary care clinics in 2014 ("Health System") and as reported in the National Ambulatory Medical Care Survey (NAMCS) in 2012 to 2013. Asthma and chronic obstructive pulmonary disease (COPD) encounter diagnoses were not Editor's Note page 854 considered inclusion criteria to minimize encounters for patients with exacerbations of these chronic diseases, which may be appropriately treated with steroids. Protocols for the health plan and health system analyses were reviewed by the Ochsner institutional review board and determined to be exempt based on federal regulations for human subjects research. Patient consent was deemed unnecessary for this retrospective observational study of adults.
Outcomes and Data Analysis. The main outcome for Health System analysis was steroid injection and for NAMCS analysis was steroid prescription. We chose steroid injection usage because we anecdotally observed that this was common practice in the Southeast United States. The NAMCS database does not query for intramuscular injections used in outpatient encounters; for this reason, we chose systemic oral steroid prescriptions. The covariates of interest included patient-, health care professional-, and encounter-specific factors. We conducted propensity score-adjusted, fixed-effects, and multivariable logistic regression analyses. Statistical significance was set at P < .05. All analyses were conducted using Stata statistical software (version 14.2; StataCorp).
Results | National Data. Almost 11% of adult outpatient encounters for ARTI included a steroid prescription. There was a significant regional variation in prescribing steroids for ARTI diagnoses, from a 13.6% prevalence in the South to a 8.3% prevalence in the Midwest ( Table 2 ). We observed substantial clinician variation with 17% never using steroid injections and 13% of clinicians using an injection more than 40% of the time (data not shown).
Conclusions | Adverse effects of systemic steroids, even for shortterm use, are well documented. Future research is needed to further explore regional and national trends in use of corticosteroids for patients with ARTIs, as it likely represents high-cost, potentially harmful care. This study revealed high rates of systemic corticosteroid use among patients with ARTIs in Louisiana and nationally. Study limitations include possible inclusion of encounters for exacerbation of chronic respiratory illnesses such as asthma or COPD and discordance in corticosteroid outcomes measured (injection vs oral). This hypothesis-generating study highlights the need to further examine use of systemic corticosteroid for ARTIs and associated safety issues.
Pharmaceutical Industry Payments and Oncologists' Selection of Targeted Cancer Therapies in Medicare Beneficiaries
Physicians and teaching hospitals in the United States receive approximately $7 billion from the pharmaceutical industry annually. 1 These payments have been associated with higher-cost, brand-name pharmaceutical prescribing.
2-4
Whether industry payments are associated with physician treatment choice in oncology is uncertain. We examined the association between oncologists' receipt of payments from pharmaceutical manufacturers and drug selection in 2 situations where there are multiple treatment options. 
